Current Partner Studies

Lupus Therapeutics has been involved in some of the most important breakthroughs in lupus research. And today, we’re helping to guide what we hope will be future breakthroughs.

Ongoing

Study Name: AMG570

Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

16 LuCIN sites (U.S. and Canada)

Study Name: AMG592

Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus

10 LuCIN sites (U.S. and Canada)

Study Name: BMS-POETYK SLE 1 & 2

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2)

23 LuCIN sites (U.S. and Canada)

Study Name: UCB

UCB Biopharma SRL

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS GO)

25 LuCIN sites (U.S. and Canada)

Study Name: Lilly-KFAJ

Eli Lilly and Company

A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) (ISLAND-SLE)

13 LuCIN sites (U.S. and Canada)

Study Name: JANSSEN ORCHID

Janssen Research & Development, LLC

A Study of Guselkumab in Participants With Active Lupus Nephritis (ORCHID-LN)

5 LuCIN sites (U.S. and Canada)

Study Name: VIB7734

Horizon Therapeutics

Study of VIB7734 for the Treatment of Moderate to Severely Active SLE (RECAST SLE)

7 LuCIN sites (U.S. and Canada)

Study Name: BIOGEN AMETHYST

Biogen

A Study to Assess the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

18 LuCIN sites (U.S. and Canada)

Study Name: BIOGEN TOPAZ

Biogen

A Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care (TOPAZ-1)

21 LuCIN sites (U.S. and Canada)

Study Name: Lilly BT01

Eli Lilly and Company

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

4 LuCIN sites (U.S. and Canada)

Study Name: VeraTx COMPASS

Vera Therapeutics

Atacicept in Subjects with Active Lupus Nephritis (COMPASS)

14 LuCIN sites (U.S. and Canada)

Past